💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Iopromide

CHEMBL1725 Phase 4 承認済み Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
791.1 g/mol
LogP
-2.1
Phase
4

This non-ionic, low-osmolality iodinated contrast agent is used for CT scans, angiography, urography, and other diagnostic imaging procedures. It reduces X-ray transparency in the tissues and blood vessels it passes through, improving the visibility of structures. Its low osmolality profile is associated with good tolerability and lower risk of adverse reactions.

分子量

791.1000 g/mol

LogP

-2.10

TPSA

169.00 Ų

リピンスキーの五則

不適合

治療領域

Hypertension Breast Cancer Cardiovascular Disease

作用機序

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COCC(=O)Nc1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)N(C)CC(O)CO)c1I

                

                

                
                

                    
InChI

                    
InChI=1S/C18H24I3N3O8/c1-24(4-9(28)6-26)18(31)12-13(19)11(17(30)22-3-8(27)5-25)14(20)16(15(12)21)23-10(29)7-32-2/h8-9,25-28H,3-7H2,1-2H3,(H,22,30)(H,23,29)

                

                

                

                    
                    

                        
Molecular Formula

                        
C18H24I3N3O8

                    

                    
                    

                        
HBD / HBA

                        
6 / 8

                    

                    
                    

                        
回転可能結合数

                        
11

                    

                    
                    
                    

                        
重原子数

                        
32

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
This non-ionic, low-osmolality iodinated contrast agent is used for CT scans, angiography, urography, and other diagnostic imaging procedures. It reduces X-ray transparency in the tissues and blood vessels it passes through, improving the visibility of structures. Its low osmolality profile is associated with good tolerability and lower risk of adverse reactions.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Iopromide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1725.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 3736.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.